Barclays analyst Carter Gould maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $54.00. The company’s shares closed last Wednesday at $51.28.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks.com, Gould is a 2-star analyst with an average return of 1.9% and a 41.3% success rate. Gould covers the Healthcare sector, focusing on stocks such as Reata Pharmaceuticals, Travere Therapeutics, and Applied Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $60.06 average price target, which is a 16.3% upside from current levels. In a report issued on January 28, J.P. Morgan also maintained a Hold rating on the stock with a $57.00 price target.
See today’s best-performing stocks on TipRanks >>
Pfizer’s market cap is currently $290.2B and has a P/E ratio of 15.35.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PFE in relation to earlier this year. Most recently, in December 2021, Albert Bourla, the Chairman & CEO of PFE bought 231,499 shares for a total of $6,193,969.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More on PFE:
- Peloton Reports Stationary Earnings; Uphill Battle Remains
- Adtalem Global Education (ATGE) Receives a Buy from Barrington
- Rosenblatt Securities Maintains a Hold Rating on CME Group (CME)
- Intel Stock: Compelling Combo of Growth and Value
- Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Akero Therapeutics (AKRO)